Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Phase 2a/2b Trial of YB-101
Key Highlights
- Merger Completed: Yarrow Bioscience, Inc. has completed its merger with VYNE Therapeutics, creating a combined entity now trading on Nasdaq under the ticker symbol YARW.
- Major Financing Secured: The company has closed private financings totaling \$200 million, expected to fund operations into 2028.
- Lead Asset – YB-101: Yarrow’s lead candidate, YB-101, is a potentially first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody, targeting the core mechanism underlying both Graves’ Disease (GD) and Thyroid Eye Disease (TED).
- Clinical Progress: Dosing has commenced in a U.S. Phase 2a/2b trial for GD (with or without TED), following FDA Fast Track Designation. Phase 2a data are expected in H2 2027.
- Global Development: GenSci, Yarrow’s Chinese partner, is running Phase 1 trials for YB-101 (GenSci-098) in China. Data from their multiple ascending dose (MAD) trial in TED patients are also expected in H2 2027.
- Reverse Stock Split: VYNE shareholders received a 1-for-50 reverse stock split prior to the merger, adjusting share counts and setting a new CUSIP for the combined company.
- Special Cash Dividend: VYNE distributed a special cash dividend of \$17.3 million (\$0.40242 per share) to shareholders and warrant holders of record as of July 22, 2026, not affected by the reverse split.
- Outstanding Shares: Post-merger, approximately 2.8 million shares of common stock are issued and outstanding, or 33.6 million fully diluted, and 28.6 million excluding equity plans and awards.
- Leadership & Governance: Experienced executive team and board, including former CEOs and partners from leading biotech and investment firms.
Detailed Developments
Merger & Financials
Yarrow Bioscience and VYNE Therapeutics have officially merged, with the combined company operating under the Yarrow Bioscience name and ticker YARW. The merger was accompanied by \$200 million in pre-closing private placements, led by RTW Investments and other top-tier biotech investors, providing sufficient runway to fund operations until at least 2028. The reverse stock split (1-for-50) reduced the outstanding share count, potentially enhancing per-share value. The new CUSIP is 92941V4.
The special dividend of \$17.3 million, or \$0.40242 per share, was paid to eligible holders as of July 22, 2026, and was unaffected by the share consolidation. After these transactions, the combined company has approximately 2.8 million shares issued (33.6 million fully diluted).
Clinical Pipeline – YB-101
Yarrow’s lead asset, YB-101, is a monoclonal antibody designed to block TSHR, the main driver of GD and TED. This approach is intended to stop disease progression quickly and could offer superior efficacy and safety compared to current therapies, which often have significant toxicity or fail to target the disease mechanism.
YB-101 is formulated for convenient subcutaneous administration and may allow infrequent dosing and future autoinjector use, supporting patient compliance and broad market adoption.
The U.S. Phase 2a/2b trial (NCT07682896) is randomized, blinded, and placebo-controlled, with two parts:
- Phase 2a: Proof-of-concept enrolling 32 patients across four cohorts. Endpoints include safety, PK/PD, efficacy (including proportion of patients euthyroid and off anti-thyroid drugs), and measures of orbitopathy for those with TED. Data expected H2 2027.
- Phase 2b: Dose-finding, expected to enroll ~200 patients, commencing H1 2028. Dose and interval selection will depend on Phase 2a results.
GenSci, Yarrow’s licensing partner in China, is evaluating YB-101 (GenSci-098) in Phase 1 SAD and MAD trials for TED and GD. Initial SAD data showed rapid, dose-dependent proof-of-mechanism and clinical responses in TED, with no meaningful safety differences versus placebo. MAD data are expected H2 2027 and will guide global development.
Leadership & Board
The executive leadership team includes:
- Rebecca V. Frey, PharmD – President & CEO
- Rachael Alford, PhD – Chief Operating Officer
- Lori Payton, PhD – Chief Development Officer
- Steve Ryder, MD – Chief Medical Officer
- Tyler Zeronda – Chief Financial Officer
The board is chaired by Bill Lundberg, MD (former CEO at Merus), and includes leaders from OrbiMed, MBX Biosciences, Merus, and Avere.
Potential Price Sensitive Information for Investors
- FDA Fast Track Designation: YB-101’s Fast Track status could expedite regulatory review, potentially accelerating time to market.
- Phase 2a/2b Clinical Milestones: The initiation of dosing and expected Phase 2a readout in H2 2027 are key catalysts. Positive data could significantly affect share value.
- Special Dividend & Share Structure: The reverse stock split and special dividend may affect trading dynamics and per-share value.
- \$200M Cash Position: Strong cash runway reduces financing risk and supports continued clinical development, a positive for investor confidence.
- Global Expansion and Partnerships: Progress in China with GenSci may open additional markets and validate YB-101’s mechanism.
- Experienced Leadership: High-caliber management and board increase credibility and execution risk mitigation.
Forward-Looking Statements & Risks
The company notes that all forward-looking statements are based on current beliefs and assumptions, subject to various risks, including failure to realize merger benefits, expense management, capital requirements, regulatory hurdles, intellectual property protection, clinical trial outcomes, competition, and potential legal proceedings. Investors should review SEC filings for a comprehensive risk overview.
Contact Information
For investor inquiries: Joyce Allaire (LifeSci Advisors) – [email protected]
For media inquiries: Michael Galfetti (Ten Bridge Communications) – [email protected]
Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. All information is based on public filings and company communications as of July 27, 2026. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. The company’s forward-looking statements are subject to risks and uncertainties as described in its SEC filings.
